Name: Hair Loss: The Two Treatments That Work, and the Aisle of Ones That Don't
Creator: Realised
Published: 2026-06-01

Summary

For androgenetic (pattern) hair loss there are exactly two-and-a-half proven levers — topical minoxidil, an oral 5-alpha-reductase inhibitor (finasteride or, off-label, dutasteride, for men), and correcting a genuine telogen-effluvium trigger like low ferritin, thyroid disease, crash dieting, or the postpartum shed — while the entire surrounding aisle (biotin in people who aren't deficient, "DHT-blocking" shampoos sold as standalone cures, saw palmetto, "hair growth" gummies) is largely unsupported by quality evidence; the finasteride sexual-side-effect fear is real but low in absolute terms,

Why Strong

Strong Evidence because the spine of the entry — minoxidil and finasteride efficacy, the dutasteride head-to-head, the reversibility of telogen effluvium, and the biotin debunk — rests on systematic reviews/meta-analyses of RCTs, a large active- and placebo-controlled trial, and consensus dermatology, which converge cleanly.

NOT Moderate because the core efficacy and debunk claims are RCT- and meta-analysis-backed and replicated independently, not merely consensus or survey-grade.

The per-sub-area split (read this, not just the headline):
• Minoxidil and the 5ARIs (efficacy): Strong — meta-analysis plus a large head-to-head RCT; the 10-year finasteride figure is supportive cohort data, not RCT-grade.
• Telogen effluvium reversibility: Strong on mechanism/triggers (textbook consensus); the exact ferritin threshold is Moderate/contested — number deferred.
• Biotin debunk: Strong — consistent across reviews and a JAAD editorial position.
• Saw palmetto / "DHT-blocking" shampoos: Emerging/weak — small, low-quality, seller-hosted, adjunct-only at best.
• Finasteride side effects: Strong for the nocebo effect and the side-effect-rate meta-analysis; Emerging/contested for persistent post-finasteride syndrome, on poor study quality. Do not let the strong core bleed credibility onto the weak alternatives, and do not let the weak PFS data scare people off a proven drug.

Practical takeaway

The framing to hold: there are two-and-a-half proven levers and an aisle of debunked or marginal ones. Triage the type of loss first, then pick the lever, then ignore the gummies.

Step one — triage the type of loss.
• Patterned and progressive (receding hairline, crown thinning, widening part) points to androgenetic alopecia — the DHT story.
• Diffuse, sudden, all-over shedding two to three months after a stressor (illness, crash diet, childbirth, surgery) points to telogen effluvium — look for a correctable trigger.
• The two can coexist, and a clinician can distinguish them. Female-pattern diffuse thinning, in particular, deserves a workup (iron, thyroid, and androgen-driven causes such as PCOS) rather than self-diagnosis.

For androgenetic alopecia — use the proven levers.
• Topical minoxidil is the accessible first lever, works for both men and women, and is independent of the DHT pathway — it is reasonable to start here and to combine it with a 5ARI.
• A 5-alpha-reductase inhibitor (oral finasteride 1 mg/day for men; dutasteride is stronger but largely off-label) is the second lever and the one that addresses the actual mechanism. This is a prescription decision with a side-effect conversation attached — see the next section.
• Set expectations honestly: these slow and partly reverse loss and require ongoing use. Stop, and the genetically programmed loss resumes. This is management, not cure.

For telogen effluvium — fix the trigger, then wait.
• Identify and correct the driver: a measured iron deficiency, thyroid disease, an over-aggressive crash diet, or simply time after childbirth or illness.
• Then be patient. Regrowth follows correction by months, not weeks, because the follicles have to re-enter the growth phase.
• Do not self-dose iron without a measured deficiency, and do not self-treat a suspected thyroid problem — both are workup-and-clinician decisions. Iron dosing is owned by iron_supplementation_repletion_and_overload; thyroid management by thyroid_dysfunction.

Ignore (or sharply discount) the aisle.
• Biotin: skip it unless you have a diagnosed deficiency, and tell your doctor if you take it before any blood test — it skews thyroid and troponin assays.
• "DHT-blocking" shampoos / ketoconazole: at most a minor adjunct, never a standalone fix.
• Saw palmetto and "hair growth" gummies: weak-to-no evidence; a marginal alternative at best, not an equivalent to the proven drugs.

Evidence detail

Why This Entry Exists

Hair loss is one of the most efficiently monetised anxieties in health, and the market has two stories. The clinic story is narrow and a little boring: pattern hair loss is genetically programmed DHT sensitivity, and only a handful of things change the trajectory. The marketing story is wide and exciting: there is always one more shampoo, gummy, serum, or "DHT-blocking" botanical that will regrow your hairline. The honest position is that the boring clinic story is mostly right, and the wide market is mostly selling.

There is a second trap on the other side. The fear of finasteride's sexual side effects — including the contested "post-finasteride syndrome" — has been amplified to the point where people abandon a genuinely proven drug and reach for unregulated "natural" alternatives that carry their own risks and no efficacy. So this entry has to hold a both-ways line: the proven treatments work, AND the side-effect risk is real-but-small-and-contested, AND the natural alternatives that fear pushes people toward mostly don't work. Suppressing the side-effect conversation is exactly what drives people into the unproven aisle.

The other thing this entry owns is the telogen effluvium versus androgenetic alopecia distinction, because it is the single most useful piece of triage. Pattern loss is patterned (crown, hairline, part-line widening) and progressive; telogen effluvium is a diffuse, reversible shed driven by a trigger — low iron, thyroid disease, rapid weight loss, fever, or childbirth — and fixing the trigger regrows it. Mistaking one for the other sends people to the wrong fix.

What bad advice this protects against, in all directions:
• "Biotin / this gummy / this collagen will regrow your hair" → overshoots. Biotin does nothing for hair in people who aren't deficient (a rare state), and it dangerously interferes with lab assays. Most "hair growth" supplements ride this myth.
• "This DHT-blocking shampoo will fix your hairline" → overstated. Ketoconazole shampoo is at best a minor adjunct (it lowers follicular DHT only modestly), not a standalone cure, and the category as marketed oversells.
• "Saw palmetto is a natural finasteride" → it is a much weaker DHT lever, on weak evidence, with no standardised dose — a marginal alternative, not an equivalent.
• "Finasteride will give you permanent sexual side effects, so avoid it" → real risk, wrong magnitude. The absolute risk is low, much of it is nocebo, and the scariest data come from the 5 mg prostate dose, not the 1 mg hair dose. Fear-driven avoidance pushes people toward the unproven natural aisle.
• "It's all genetic, nothing works" → false in the other direction. Minoxidil and a 5ARI are RCT-proven, and a real telogen-effluvium trigger is correctable.
• "Just take iron / thyroid stuff and your hair will grow" → only if you actually have a deficiency or thyroid disease driving a shed. Self-dosing iron without a measured deficiency is its own harm; this entry defers dosing.

This entry owns the DHT/genetic mechanism of pattern loss, the proven treatments, the telogen-effluvium-versus-AGA distinction, the supplement debunk, and the honest handling of the finasteride side-effect debate. It defers iron dosing to iron_supplementation_repletion_and_overload and thyroid management to thyroid_dysfunction.

Evidence

Organised by sub-area, tier signal inline. Read the tiers: the proven-treatment and debunk claims are Strong; the post-finasteride-syndrome question is the genuinely contested, weak part.

The proven core — minoxidil and the 5-alpha-reductase inhibitors (Strong Evidence).

1. A systematic review and meta-analysis found minoxidil, finasteride, and low-level laser therapy effective for hair growth in men with AGA, and minoxidil effective in women with AGA. This is the meta-analytic backbone that establishes these as the evidence-backed options against a sea of alternatives. (Gupta AK et al., "The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis," J Am Acad Dermatol, 2017. Strong Evidence — systematic review/meta-analysis of RCTs. BOTH-WAYS: the lead author has historically disclosed consulting/speaking ties to dermatology manufacturers, worth flagging on any single-author review, but it does not undercut the pooled RCT signal.)

2. Oral finasteride 1 mg/day has durable, replicated efficacy for men. The pivotal one-year placebo-controlled trials established hair-count gains versus placebo, and a long-term Japanese cohort of 532 men over ten years reported 91.5% showing improvement and 99.1% showing prevention of further progression. (Pivotal RCTs: Kaufman KD et al. for the Finasteride Male Pattern Hair Loss Study Group, J Am Acad Dermatol, 1998. Long-term figure: a 10-year Japanese finasteride cohort, n=532, summarised in AGA reviews. Strong Evidence for the pivotal RCTs; the 10-year figure is observational cohort data and is framed as supportive, not RCT-grade. BOTH-WAYS: the pivotal trials were Merck-funded — the manufacturer — but the effect has since been replicated in independent meta-analyses, which is the cui-bono check that matters.)

3. Dutasteride outperformed finasteride on hair count in a large head-to-head RCT. In 917 men randomised across dutasteride 0.02/0.1/0.5 mg, finasteride 1 mg, and placebo, dutasteride 0.5 mg/day beat finasteride 1 mg/day on hair count and width at 24 weeks. This confirms the whole 5ARI class works and that dutasteride is the stronger (mostly off-label) option. (Gubelin Harcha W et al., "A randomized, active- and placebo-controlled study of different doses of dutasteride versus placebo and finasteride...," J Am Acad Dermatol, 2014. Strong Evidence — large multi-arm placebo- and active-controlled RCT. BOTH-WAYS: GlaxoSmithKline, the dutasteride manufacturer, sponsored it, so pro-dutasteride framing is expected; and dutasteride is approved for AGA only in a few countries — off-label elsewhere — which is a real caveat.)

The reversible-shed sub-area — telogen effluvium versus AGA (Strong on mechanism, Moderate on the iron threshold).

4. Telogen effluvium is a diffuse, non-scarring, REVERSIBLE shed; correcting the trigger regrows the hair. Triggers include thyroid disease, low iron, rapid weight loss, fever, and childbirth; postpartum shedding begins roughly one to five months after delivery and typically resolves within six to twelve months. Serum ferritin, not haemoglobin, is the relevant iron marker, with telogen-effluvium-associated cutoffs reported around 24–25 ng/mL. (Hughes EC, Saleh D, "Telogen Effluvium," StatPearls/NCBI Bookshelf, current; ferritin cutoff from a cross-sectional comparative study. Strong Evidence for the reversibility/mechanism and trigger list — textbook dermatology consensus; the exact ferritin threshold is Moderate/contested, observational. No industry conflict; the contested part is the precise number, which this entry does not prescribe — dosing is deferred.)

The debunked / marginal aisle (Strong for the debunk; weak for the "alternatives").

5. Biotin does nothing for hair in people who aren't deficient — and interferes with lab tests. Benefit is confined to rare deficiency states (biotinidase deficiency, uncombable hair syndrome, isotretinoin/valproate use). Dermatology reviews and a JAAD editorial position it as providing no benefit in the non-deficient while dangerously skewing immunoassays such as thyroid and troponin. (Patel DP, Swink SM, Castelo-Soccio L, "A Review of the Use of Biotin for Hair Loss," Skin Appendage Disord, 2017; JAAD editorial "First do no harm — biotin for hair and nails," 2024. Strong Evidence for the debunk, consistent across reviews. The cui-bono here runs toward the sellers: the hair-gummy/biotin market profits from keeping the myth alive.)

6. Saw palmetto is a weak DHT lever, not a natural finasteride. It reduces DHT far less than finasteride (roughly ~32% versus finasteride's ~60–70% range), low-quality trials report modest improvement in only a minority of users, and it is unregulated with no standardised dose. (Evron E, Juhasz M, Babadjouni A, Mesinkovska NA, "Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia," Skin Appendage Disord, 2020; corroborated by a more recent critical review in Int J Dermatol. Emerging/weak — small RCTs and cohorts, no head-to-head superiority, regulatory concerns. BOTH-WAYS: many favourable saw-palmetto write-ups are hosted by supplement or telehealth sellers — direct commercial conflict; the peer-reviewed reviews are the trustworthy anchor.)

7. Ketoconazole 2% shampoo is at best a minor adjunct, not a standalone "DHT-blocking" cure. It lowers follicular DHT only modestly and is roughly a fifth as effective as finasteride/dutasteride, and it is not approved for hair loss. The "DHT-blocking shampoo" category as marketed overstates this. (Pierard-Franchimont C et al., "Ketoconazole Shampoo: Effect of Long-Term Use in Androgenic Alopecia," Dermatology, 1998; plus a study of ketoconazole as an adjunct to finasteride. Moderate-to-Emerging — small studies, adjunct-only signal; the standalone-shampoo cure claim is unsupported. The shampoo-cure framing is pushed by DTC/telehealth sellers; the clinical literature only supports adjunct use.)

The contested side-effect sub-area — real but low and nocebo-inflated (Strong on nocebo; contested on PFS).

8. Finasteride sexual side effects are real but low in absolute terms and substantially nocebo-driven. In a randomised study, 43.6% of men told about sexual side effects reported them versus 15.3% of those not told (P=.03). A meta-analysis of finasteride/dutasteride for AGA found measurable but modest sexual-adverse-event rates. Persistent symptoms — "post-finasteride syndrome" — are reported but inconsistently characterised and built on poor-quality studies. (Mondaini N et al., "Finasteride 5 mg and Sexual Side Effects: How Many of these are Related to a Nocebo Phenomenon?" J Sex Med, 2007; an Acta Derm Venereol 2018 meta-analysis of adverse sexual effects of finasteride/dutasteride in AGA; PFS reviews. Strong Evidence for the nocebo finding and the side-effect-rate meta-analysis; Emerging/contested for persistent PFS, on low study quality. BOTH-WAYS: the nocebo data come partly from the 5 mg prostate dose, higher than the 1 mg hair dose, so AGA-specific absolute risk is likely lower; and the PFS literature is heavily shaped by an advocacy foundation and litigation. Both biases must be named — pharma minimises, advocacy amplifies.)

Mechanism

Why pattern loss happens, and why DHT is the lever. Androgenetic alopecia is genetically programmed sensitivity of scalp follicles to dihydrotestosterone (DHT), the potent androgen produced when 5-alpha-reductase converts testosterone. In susceptible follicles DHT progressively miniaturises the hair: each growth cycle produces a finer, shorter, less-pigmented shaft until the follicle effectively stops producing visible hair. This is why the two drug levers target two different points. Finasteride and dutasteride inhibit 5-alpha-reductase, lowering scalp DHT and halting (and partly reversing) miniaturisation — finasteride blocks mainly the type II enzyme, dutasteride blocks types I and II, which is why dutasteride lowers DHT more and tends to work harder. Minoxidil works by a different mechanism entirely — it is a vasodilator/potassium-channel opener that prolongs the growth (anagen) phase and enlarges follicles, which is why it complements a 5ARI rather than duplicating it.

Why telogen effluvium is a different animal. Normal hair cycles between growth (anagen), transition, and rest (telogen), and a fixed fraction is always resting and shedding. A systemic stressor — a thyroid swing, iron depletion, a crash diet, a fever, or the hormonal cliff after childbirth — pushes an abnormally large fraction of follicles into telogen at once. Two to three months later they shed together: a diffuse, frightening, but reversible loss. Because the follicles are not destroyed, removing the trigger lets them re-enter the growth phase and regrow. This is the mechanistic reason the triage matters: pattern loss needs a DHT lever, a telogen shed needs the trigger fixed (and then waits).

Why most of the aisle can't work. Biotin is a cofactor for carboxylase enzymes; supplementing it past sufficiency adds nothing to hair because the enzymes were already saturated — there is no rate-limiting step to relieve. "DHT-blocking" shampoos contact the scalp briefly and lower follicular DHT only marginally; they cannot match a systemic 5ARI. Saw palmetto is a weak, variable 5-alpha-reductase inhibitor with no standardised content, so even where it nudges DHT it does so far less than finasteride. None of these reach the lever the way the proven treatments do.

Risks And Contraindications

• Finasteride side effects: name them, size them correctly. Sexual side effects (reduced libido, erectile or ejaculatory changes) are real but low in absolute terms and substantially nocebo-driven, and the scariest figures come from the 5 mg prostate dose, not the 1 mg hair dose. Persistent post-finasteride symptoms are reported but rest on poor-quality evidence and are genuinely contested. The honest move is to disclose this, not suppress it — suppression is what pushes people toward unproven "natural" alternatives.
• New or worsening erectile dysfunction is itself a red flag worth a doctor. ED can be an early marker of cardiovascular disease, so do not simply blame a drug or chase a supplement — see erectile_dysfunction_lifestyle and get it assessed.
• 5ARIs and the prostate. Finasteride/dutasteride lower PSA (roughly halving it), which must be accounted for in prostate-cancer screening; the BPH/prostate context is owned by bph_prostate_lifestyle. 5ARIs are contraindicated in pregnancy and women who may become pregnant must not handle crushed/broken tablets (risk to a male fetus).
• Female diffuse thinning needs a diagnosis, not a guess. It can reflect iron deficiency, thyroid disease, or an androgen-driven cause such as PCOS — each needs proper assessment rather than over-the-counter self-treatment.
• Don't self-dose iron. Iron overload is harmful; only correct a measured deficiency, and defer dosing to iron_supplementation_repletion_and_overload.
• Biotin can cause a dangerous lab error. High-dose biotin skews immunoassays (thyroid function, troponin) and has produced clinically misleading results. Disclose any biotin use before blood tests.
• "Manageable not cured" is the realistic expectation for pattern loss. The proven treatments require ongoing use; stopping resumes the genetic trajectory.
• See a clinician for sudden diffuse shedding, patchy/scarring loss (a different disease class entirely), scalp inflammation, or hair loss with other systemic symptoms.

Controversy

Nature: a solid, RCT-backed core (minoxidil, the 5ARIs, the reversibility of telogen effluvium) wrapped around a genuinely contested side-effect question (post-finasteride syndrome), with commercial and advocacy pressure pulling hard in both directions. The proven-treatment camp can minimise harms; the natural-alternative and advocacy camp amplifies them to sell unproven products and a litigation narrative.

Position A — "Minoxidil and the 5ARIs are the only robustly proven treatments, and correcting a real telogen-effluvium trigger reliably regrows that shed." The grounded clinical take.
• Best evidence: meta-analysis backing for minoxidil and finasteride, a head-to-head RCT for dutasteride, durable long-term cohort data for finasteride, and textbook reversibility of trigger-driven telogen effluvium once the cause (iron, thyroid, crash diet, postpartum) is corrected.
• Where it's wrong if pushed too far: it must not minimise the real (if small and contested) side-effect risk, and it must not promise "cure" — pattern loss resumes when treatment stops.

Position B — "The hair-supplement aisle is largely unsupported, and the finasteride side-effect fear is real-but-small-and-contested, not a reason to switch to a 'natural' alternative." The honest-limits take.
• Best evidence: the biotin debunk is consistent across reviews; saw palmetto and ketoconazole shampoo are weak/adjunct at best; and the nocebo data plus the 5 mg-versus-1 mg dose distinction show the side-effect fear is inflated relative to absolute risk at the hair dose.
• Where it's wrong if pushed too far: it must not dismiss persistent post-finasteride symptoms as pure nocebo — they are reported, study quality aside — and it must not imply certainty about reversibility either way.

The funding/bias dimension — cui bono, both ways. Pulling toward the drugs: Merck (finasteride) and GlaxoSmithKline (dutasteride) funded the pivotal trials and have obvious incentive to minimise side effects — checked by independent replication in meta-analyses. Pulling the other way: a multibillion-dollar supplement and direct-to-consumer telehealth market profits from both the biotin myth and from amplifying finasteride fear to sell unproven "natural" alternatives, and much of the favourable saw-palmetto and ketoconazole content is hosted by sellers. A post-finasteride advocacy body and associated litigation have a stake in maximising the PFS narrative. The least-conflicted, most-replicated signals — the meta-analytic efficacy of minoxidil/finasteride, the biotin debunk, and the nocebo effect — are the load-bearing claims.

Realised Position: There are two-and-a-half proven levers — topical minoxidil, a 5-alpha-reductase inhibitor for pattern loss in men, and correcting a genuine telogen-effluvium trigger — and an aisle of debunked or marginal ones. Realised names the small, real, often-reversible-but-contested side-effect risk of finasteride out loud, specifically at the 1 mg hair dose, rather than suppressing it, because suppression is exactly what drives people toward unregulated "natural" products that carry their own risks and no efficacy. We do not present biotin (outside deficiency), DHT-blocking shampoos as cures, or saw palmetto as equivalents to the proven drugs. We defer iron dosing to iron_supplementation_repletion_and_overload and thyroid management to thyroid_dysfunction, and we route new erectile dysfunction and diffuse female thinning to a clinician rather than a supplement shelf.

Cross-Pillar Connections

Hair loss is genuinely cross-pillar — a dermatological condition (physical/skin) whose drivers and fixes reach into hormonal androgen physiology, iron and thyroid status (diet/metabolic), and the evidence-literacy needed to resist a heavily-marketed aisle.
• Cross-pillar (iron_supplementation_repletion_and_overload): owns iron deficiency assessment and dosing; this entry names low ferritin as a reversible telogen-effluvium trigger but defers the "how much iron" question there, including the overload risk of self-dosing.
• Cross-pillar (thyroid_dysfunction): owns thyroid assessment and management; thyroid disease is a classic telogen-effluvium trigger this entry flags but does not treat.
• Cross-pillar (universal_nearuniversal_supplementation): the broader "which supplements are actually worth taking" frame; the biotin/hair-gummy debunk here is a case study in the same discipline.
• Cross-pillar (publication_bias_and_evidence_distortion): owns the methods for reading conflicted literature — manufacturer-funded trials, seller-hosted reviews, and advocacy-amplified harm narratives all appear in this topic.
• Cross-pillar (erectile_dysfunction_lifestyle): the finasteride sexual-side-effect conversation overlaps here, and new ED is a cardiovascular red flag this entry routes to.
• Cross-pillar (bph_prostate_lifestyle): 5ARIs are also prostate drugs; the PSA-lowering and BPH-versus-cancer screening context lives there.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd move post-finasteride syndrome from "contested/poor-quality" toward a defined absolute risk if a large, well-powered, blinded RCT or registry quantified persistent sexual or cognitive symptoms specifically at the 1 mg AGA dose with a clean placebo arm. That could change how strongly we frame the side-effect caveat.
• We'd upgrade saw palmetto or a "hair" supplement out of the debunk if a high-quality RCT showed non-inferiority to finasteride on hair count.
• We'd revisit biotin if robust evidence emerged that it benefits hair in non-deficient people — none exists currently.
• We'd state an actual ferritin number if a definitive intervention trial fixed the threshold at which iron repletion regrows telogen-effluvium hair, rather than deferring dosing.
• What would NOT move us: the meta-analytic efficacy of minoxidil and finasteride, the head-to-head dutasteride result, the reversibility of trigger-driven telogen effluvium, and the biotin debunk are robust and independently replicated. Manufacturer funding of the pivotal trials is real but the effect replicates in independent meta-analyses, which is the check that matters.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs hard in both directions, which is why the least-conflicted signals are the anchors.
• The pro-drug end: Merck (finasteride) and GlaxoSmithKline (dutasteride) funded the pivotal trials and have an obvious incentive to minimise side effects. The check on this is independent replication — the efficacy survives in meta-analyses the manufacturers did not run.
• The anti-drug / pro-natural end: a multibillion-dollar supplement and DTC-telehealth market profits from the biotin/gummy myth and from amplifying finasteride fear to sell unproven "natural" alternatives. Much of the favourable saw-palmetto and ketoconazole-shampoo content is hosted by the very companies selling those products, a direct commercial conflict; the peer-reviewed reviews are the trustworthy anchor.
• The advocacy/litigation end: a post-finasteride-syndrome advocacy body and associated litigation have a financial and narrative stake in maximising the persistent-side-effect story, just as pharma has a stake in minimising it. The honest entry sizes the risk from the cleanest data (the nocebo RCT, the 1 mg-versus-5 mg dose distinction) rather than from either advocacy or pharma framing.
• The clean signal: the meta-analytic efficacy of minoxidil and finasteride, the biotin debunk, and the nocebo effect are the least-conflicted and most-replicated claims — and they are exactly the ones the entry leans on. The advice that benefits no seller (use the two proven levers, fix a real trigger, see a doctor, skip the aisle) is the part with the cleanest evidence, which is the tell.

Hair Loss: The Two Treatments That Work, and the Aisle of Ones That Don't